Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is the 2018 Trial of Oral THC Cannabis for Sleep Apnoea Clinically Significant? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The 2018 oral THC trial for OSA  investigated the effects of oral THC, specifically dronabinol, on obstructive sleep apnoea outcomes. This study is frequently cited when evaluating cannabinoid therapies for sleep-disordered breathing due to its structured design and objective measurements of respiratory events. 

Am I eligible for medical cannabis for pain relief?

Key Insights from the 2018 Trial 

The 2018 oral THC trial for OSA aimed to reduce apnoea-hypopnea index (AHI) while maintaining tolerable side-effect profiles. 

Efficacy Outcomes 

Participants in the 2018 oral THC trial for OSA showed modest reductions in AHI, suggesting a potential benefit in stabilising airway activity during sleep. 

Clinical Relevance 

Analysis of oral THC’s trial significance indicates that while improvements were measurable, the reductions in apnoea events may not translate into meaningful clinical outcomes for all patients, highlighting the need for cautious interpretation. 

Safety Profile 

The trial noted that dronabinol’s use was generally well-tolerated, though some participants experienced mild sleepiness or gastrointestinal discomfort, emphasising careful dose management. 

Broader Implications 

The dronabinol’s clinical trial contributes to understanding cannabinoid therapy as a potential adjunct for OSA, but larger, longer-term studies are required to establish robust evidence for widespread clinical application. 

The 2018 oral THC trial for OSA and evaluations of oral THC’s trial significance support the feasibility of cannabinoid therapy for OSA, yet clinical adoption remains limited pending further validation from expanded dronabinol’s clinical trial research. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea). 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories